Weekly Investment Analysts’ Ratings Changes for Rhythm Pharmaceuticals (RYTM)

Rhythm Pharmaceuticals (NASDAQ: RYTM) has recently received a number of price target changes and ratings updates:

• 5/9/2026 – Rhythm Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/7/2026 – Rhythm Pharmaceuticals had its price target raised by Canaccord Genuity Group Inc. from $140.00 to $143.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Rhythm Pharmaceuticals had its price target raised by Royal Bank Of Canada from $136.00 to $137.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – Rhythm Pharmaceuticals had its price target raised by Wells Fargo & Company from $143.00 to $144.00. They now have an “overweight” rating on the stock.
• 4/21/2026 – Rhythm Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/19/2026 – Rhythm Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/11/2026 – Rhythm Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/18/2026 – Rhythm Pharmaceuticals had its price target lowered by HC Wainwright from $110.00 to $100.00. They now have a “buy” rating on the stock.
• 3/17/2026 – Rhythm Pharmaceuticals had its price target lowered by Citigroup Inc. from $136.00 to $131.00. They now have a “buy” rating on the stock.
• 3/17/2026 – Rhythm Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $140.00 to $130.00. They now have an “outperform” rating on the stock.
• 3/17/2026 – Rhythm Pharmaceuticals had its price target lowered by Citizens Jmp from $176.00 to $152.00. They now have a “market outperform” rating on the stock.
• 3/17/2026 – Rhythm Pharmaceuticals had its price target lowered by Bank of America Corporation from $145.00 to $139.00. They now have a “buy” rating on the stock.
• 3/17/2026 – Rhythm Pharmaceuticals had its price target lowered by Needham & Company LLC from $139.00 to $130.00. They now have a “buy” rating on the stock.
• 3/17/2026 – Rhythm Pharmaceuticals had its price target lowered by Morgan Stanley from $150.00 to $136.00. They now have an “overweight” rating on the stock.

Insiders Place Their Bets

In other news, CAO Christopher Paul German sold 5,614 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total value of $502,789.84. Following the transaction, the chief accounting officer owned 160 shares of the company’s stock, valued at approximately $14,329.60. This trade represents a 97.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Hunter C. Smith sold 4,385 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $101.26, for a total transaction of $444,025.10. Following the completion of the transaction, the chief financial officer directly owned 110,512 shares in the company, valued at approximately $11,190,445.12. This represents a 3.82% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 17,926 shares of company stock worth $1,737,778. Insiders own 5.90% of the company’s stock.

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.